Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
Authors
Keywords
-
Journal
Neurology-Neuroimmunology & Neuroinflammation
Volume 10, Issue 6, Pages e200167
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-10
DOI
10.1212/nxi.0000000000200167
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes
- (2023) Gauruv Bose et al. Multiple Sclerosis and Related Disorders
- Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial
- (2023) John R Corboy et al. LANCET NEUROLOGY
- Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
- (2022) Pascal Benkert et al. LANCET NEUROLOGY
- Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis
- (2022) Ayla Pauwels et al. Multiple Sclerosis Journal
- High or increasing serum NfL is predictive of impending multiple sclerosis relapses
- (2022) Simon Thebault et al. Multiple Sclerosis and Related Disorders
- Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
- (2022) Christian Barro et al. Neurology-Neuroimmunology & Neuroinflammation
- Serum neurofilament light in MS: The first true blood-based biomarker?
- (2021) Simon Thebault et al. Multiple Sclerosis Journal
- Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis
- (2021) Maija Saraste et al. Multiple Sclerosis and Related Disorders
- Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
- (2021) Jan Hillert et al. Frontiers in Neurology
- Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults
- (2021) May A. Beydoun et al. Translational Psychiatry
- Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice
- (2021) Paola Valentino et al. Multiple Sclerosis and Related Disorders
- Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis
- (2021) Ting-Yi Lin et al. Neurology-Neuroimmunology & Neuroinflammation
- Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment
- (2020) Gauruv Bose et al. Multiple Sclerosis Journal
- Blood neurofilament light levels segregate treatment effects in multiple sclerosis
- (2020) Bénédicte Delcoigne et al. NEUROLOGY
- Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations
- (2020) Mark S. Freedman et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
- (2020) Mattia Rosso et al. Annals of Clinical and Translational Neurology
- A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models
- (2020) Enrico Longato et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity
- (2020) Anne-Laure Kaminsky et al. JOURNAL OF NEUROLOGY
- Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity
- (2020) Xavier Ayrignac et al. Scientific Reports
- Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
- (2020) Tobias Monschein et al. JOURNAL OF NEUROLOGY
- SUSTAINED DISEASE REMISSION AFTER DISCONTINUATION OF DISEASE MODIFYING TREATMENTS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
- (2020) Matteo Pasca et al. Multiple Sclerosis and Related Disorders
- Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
- (2019) Ester Cantó et al. JAMA Neurology
- High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS
- (2019) Simon Thebault et al. Neurology-Neuroimmunology & Neuroinflammation
- Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes
- (2019) Hajime Yano et al. Multiple Sclerosis and Related Disorders
- Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
- (2018) Ilya Kister et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60
- (2018) Le H Hua et al. Multiple Sclerosis Journal
- Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60
- (2018) Le H Hua et al. Multiple Sclerosis Journal
- Serum GFAP as a biomarker for disease severity in multiple sclerosis
- (2018) A. Abdelhak et al. Scientific Reports
- Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
- (2018) Tanuja Chitnis et al. Annals of Clinical and Translational Neurology
- Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI
- (2017) Dominik S. Meier et al. JOURNAL OF NEUROIMAGING
- Serum neurofilament is associated with progression of brain atrophy and disability in early MS
- (2017) Jens Kuhle et al. NEUROLOGY
- Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
- (2017) Lenka Novakova et al. NEUROLOGY
- Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
- (2016) Marcus D’Souza et al. Multiple Sclerosis Journal
- Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors
- (2016) Gabriel Bsteh et al. Multiple Sclerosis Journal
- Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
- (2016) Marcus D’Souza et al. Multiple Sclerosis Journal
- Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors
- (2016) Gabriel Bsteh et al. Multiple Sclerosis Journal
- Classification accuracy and cut point selection
- (2012) Xinhua Liu STATISTICS IN MEDICINE
- On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
- (2011) Hajime Uno et al. STATISTICS IN MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started